利妥昔单抗对临床前期类风湿关节炎患者报告结局的影响:PRAIRI 研究 2 年数据
PRAIRI 研究为随机双盲安慰剂对照试验,78 例类风湿关节炎风险个体接受单次安慰剂或 1000 mg 利妥昔单抗联合 100 mg 甲泼尼龙及抗组胺药。2 年随访时,利妥昔单抗组与安慰剂组在 HAQ 评分、EQ-5D、VAS 疼痛等患者报告结局上均无显著变化,关节炎发病时的感知疾病严重程度亦无显著影响。
要点
- 单次利妥昔单抗联合甲泼尼龙对类风湿关节炎风险个体 2 年患者报告结局无有意义的可测量积极影响
- 24 个月时 HAQ 评分平均差异 0.07±0.16,EQ-5D 平均差异 -0.02±0.05,VAS 疼痛平均差异 11.11±7.40
- 治疗对临床发病时感知关节炎严重程度无显著影响
核心结论
- 对类风湿关节炎风险个体给予单次利妥昔单抗联合甲泼尼龙,在 2 年随访后对患者报告结局和/或关节炎发展时的感知疾病严重程度无有意义的可测量积极影响。
研究设计与样本
- PRAIRI 研究为随机、双盲、安慰剂对照试验,78 例类风湿关节炎风险个体接受单次安慰剂或 1000 mg 利妥昔单抗,两组均联用 100 mg 甲泼尼龙及抗组胺药作为辅助用药。
- 在基线及 1、4、6、12、24 个月使用视觉模拟量表疼痛、健康评估问卷残疾指数评分、EuroQol 五维度量表及 36 项简短健康调查的躯体和精神成分评分收集生活质量数据。
主要发现
- 24 个月时患者报告结局评分显示,利妥昔单抗组与安慰剂组相比生活质量无显著变化:HAQ 评分平均差异 0.07±0.16,EQ-5D 平均差异 -0.02±0.05,VAS 疼痛平均差异 11.11±7.40。
- 未发现治疗对临床发病(关节炎)时感知关节炎严重程度有显著影响。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Early treatment of individuals at risk of developing rheumatoid arthritis (RA-risk) in the preclinical phase has the potential to positively impact both patients and society by preventing disease onset and improving patients' quality of life. The PRAIRI study was a randomised, double-blind, placebo-controlled trial with the B-cell depleting agent rituximab (RTX), which resulted in a significant delay of arthritis development of up to 12 months in seropositive RA-risk individuals. Here, we report our findings on patient-reported outcomes (PROs) in this study population. METHODS: Seventy-eight RA-risk individuals were treated with one single dose of either placebo (PBO) or 1000 mg RTX plus 100 mg methylprednisolone (MP) and anti-histamines, regardless of treatment allocation, as co-medication. Data on quality of life were collected at baseline and 1, 4, 6, 12 and 24 months using established PRO questionnaires (visual analogue scale (VAS) pain, health assessment questionnaire disability index (HAQ-DI) score, EuroQol five dimension (EQ-5D) and both physical and mental component score of the 36-item short-form heath survey (SF-36)). RESULTS: No significant changes in quality of life over a 2 year follow-up were observed in at-risk individuals treated with RTX compared to PBO given the PRO scores at 24 months (mean difference±SEM: HAQ score=0.07±0.16; EQ-5D=-0.02±0.05; VAS pain=11.11±7.40). Furthermore, no significant effect of treatment on perceived arthritis severity at the time of clinically manifest disease (arthritis) was found. CONCLUSION: One single dose of RTX plus MP administered to RA-risk individuals does not have a meaningful and measurable positive effect on PROs after 2 years of follow-up and/or perceived disease severity at the time of arthritis development. TRIAL REGISTRATION NUMBER: Trial registered at EU Clinical Trial Register, EudraCT Number: 2009-010955-29 (https://www.clinicaltrialsregister.eu/ctr-search/search?query=Prevention+of+RA+by+B+cell+directed+therapy).
引用
- Frazzei G, Cramer SHM, Landewé RBM, et al. The effect of rituximab on patient reported outcomes in the preclinical phase of rheumatoid arthritis: 2 year data from the PRAIRI study. RMD Open. 2024. PMID: 39424405. doi:10.1136/rmdopen-2024-004622
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。